methylprednisolone and Idiopathic Parkinson Disease

methylprednisolone has been researched along with Idiopathic Parkinson Disease in 6 studies

Research

Studies (6)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	3 (50.00)	29.6817
2010's	3 (50.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Chen, CH; Chou, YC; Huang, WY; Ju, UH; Kao, CH; Lin, CL; Lin, CS; Lin, KT; Lin, TY; Liu, FC; Shen, CH; Yang, TY	1
Bailey, M; Gera, A; Witek, N	1
Ait Benhaddou, EH; Benomar, A; Hamaz, S; Lachhab, L; Regragui, W; Yahyaoui, M	1
Becker, G; Csoti, I; Günthner-Lengsfeld, T; Naumann, M; Reiners, K; Schneider, C; Wunderlich, S	1
Asoh, T; Metoki, N; Sato, Y; Satoh, K	1
Clarke, CE	1

Trials

1 trial(s) available for methylprednisolone and Idiopathic Parkinson Disease

Article	Year
Efficacy of methylprednisolone pulse therapy on neuroleptic malignant syndrome in Parkinson's disease. Journal of neurology, neurosurgery, and psychiatry, 2003, Volume: 74, Issue:5 Topics: Aged; Antiparkinson Agents; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Methylprednisolone; Neuroleptic Malignant Syndrome; Neuroprotective Agents; Parkinson Disease; Pulse Therapy, Drug; Severity of Illness Index; Time Factors; Treatment Outcome	2003

Article

Year

Efficacy of methylprednisolone pulse therapy on neuroleptic malignant syndrome in Parkinson's disease.

Journal of neurology, neurosurgery, and psychiatry, 2003, Volume: 74, Issue:5

Topics: Aged; Antiparkinson Agents; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Methylprednisolone; Neuroleptic Malignant Syndrome; Neuroprotective Agents; Parkinson Disease; Pulse Therapy, Drug; Severity of Illness Index; Time Factors; Treatment Outcome

2003

Other Studies

5 other study(ies) available for methylprednisolone and Idiopathic Parkinson Disease

Article	Year
Risk of Parkinson disease in Sjögren syndrome administered ineffective immunosuppressant therapies: A nationwide population-based study. Medicine, 2019, Volume: 98, Issue:14 Topics: Adult; Aged; Anti-Inflammatory Agents; Antirheumatic Agents; Comorbidity; Female; Humans; Hydroxychloroquine; Immunosuppression Therapy; Incidence; Male; Methylprednisolone; Middle Aged; Muscarinic Agonists; National Health Programs; Parkinson Disease; Pilocarpine; Quinuclidines; Retrospective Studies; Risk Factors; Sjogren's Syndrome; Taiwan; Thiophenes	2019
Pearls & Oy-sters: CAA-related inflammation presents as subacute cognitive decline in a patient with Parkinson disease. Neurology, 2019, 06-04, Volume: 92, Issue:23 Topics: Aged; Brain Edema; Cerebral Amyloid Angiopathy; Cognitive Dysfunction; Frontal Lobe; Glucocorticoids; Humans; Inflammation; Magnetic Resonance Imaging; Male; Methylprednisolone; Parkinson Disease; White Matter	2019
Parkinsonism as first manifestation of lupus. Revue neurologique, 2012, Volume: 168, Issue:12 Topics: Adult; Anti-Inflammatory Agents; Biopsy; Cyclophosphamide; Female; Humans; Immunosuppressive Agents; Kidney; Lupus Erythematosus, Systemic; Magnetic Resonance Imaging; Methylprednisolone; Parkinson Disease; Prednisone	2012
Camptocormia in Parkinson's disease mimicked by focal myositis of the paraspinal muscles. Movement disorders : official journal of the Movement Disorder Society, 2002, Volume: 17, Issue:3 Topics: Anti-Inflammatory Agents; Back; Biopsy, Needle; Creatine Kinase; Diagnosis, Differential; Humans; Kyphosis; Magnetic Resonance Imaging; Male; Methylprednisolone; Middle Aged; Myositis; Parkinson Disease; Posture; Treatment Outcome	2002
Efficacy of methyprednisolone pulse therapy on neuroleptic malignant syndrome in Parkinson's disease. Journal of neurology, neurosurgery, and psychiatry, 2004, Volume: 75, Issue:3 Topics: Antiparkinson Agents; Humans; Incidence; Japan; Methylprednisolone; Neuroleptic Malignant Syndrome; Neuroprotective Agents; Parkinson Disease	2004